Functional and Morphologic Aspects of Intravitreal Triamcinolone for Uveitis-associated Cystoid Macular Edema

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Marion Munk, Medical University of Vienna
ClinicalTrials.gov Identifier:
NCT01299129
First received: February 17, 2011
Last updated: December 24, 2011
Last verified: December 2011
  Purpose

Purpose:

To evaluate the effect of intravitreal triamcinolone acetonide (IVTA) on uveitis-associated cystoid macular edema (CME) using high resolution optical coherence tomography (SDOCT) in conjunction with thorough visual function testing.

Methods:

28 patients with uveitis-associated CME were examined before intravitreal triamcinolone injection (IVTA) (v1) and at day 1 (v2), week 1 (v3) and month 1 (v4) after injection. Retinal anatomy was evaluated using Cirrus HD-OCT (Carl Zeiss Meditec). Visual function testing consisted of assessing ETDRS distance visual acuity (VA), reading acuity and reading speed using a standardized German-language test (Radner Reading charts), contrast sensitivity using Pelli-Robson Contrast Sensitivity charts and fundus-controlled microperimetry using the MP-1 Microperimeter (Nidek). Here we utilized a cartesian grid consisting of a central locus and three concentric box-shaped stimulation areas. The changes of retinal anatomy over time were compared to the respective outcome of visual function.


Condition
Uveitis Related Cystoid Macular Edema

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Functional and Morphologic Aspects of Intravitreal Triamcinolone for Uveitis-associated Cystoid Macular Edema

Resource links provided by NLM:


Further study details as provided by Medical University of Vienna:

Enrollment: 30
Study Start Date: June 2009
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

uveitis ambulance patients of the department of ophthalmology, medical university vienna

Criteria

Inclusion Criteria:

  • intraocular inflammation
  • able to read
  • > 18 years old

Exclusion Criteria:

  • cataract
  • amblyopia
  • dyslexia
  • already applicated intravitreal triamcinolone for current cystoid macular edema
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01299129

Locations
Austria
Medical University Vienna
Vienna, Austria, 1090
Sponsors and Collaborators
Medical University of Vienna
  More Information

No publications provided

Responsible Party: Marion Munk, Dr. med. univ, Medical University of Vienna
ClinicalTrials.gov Identifier: NCT01299129     History of Changes
Other Study ID Numbers: 070/2009
Study First Received: February 17, 2011
Last Updated: December 24, 2011
Health Authority: Austria: Federal Ministry for Health and Women

Keywords provided by Medical University of Vienna:
Uveitis
Cystoid macular edema
microperimetry
functional visual acuity
intravitreal triamcinolone

Additional relevant MeSH terms:
Edema
Macular Edema
Uveitis
Chorioretinitis
Signs and Symptoms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Uveal Diseases
Retinitis
Choroiditis
Choroid Diseases
Uveitis, Posterior
Panuveitis
Triamcinolone hexacetonide
Triamcinolone
Triamcinolone Acetonide
Triamcinolone diacetate
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Immunosuppressive Agents
Immunologic Factors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on July 29, 2014